15 Cushing
Irvine, CA 92618
United States
949 409 7600
https://www.oncocyte.com
Settore/i:
Settore:
Impiegati a tempo pieno: 43
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Joshua Riggs | President, CEO & Director | 373,2k | N/D | 1983 |
Mr. James Liu | Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer | 192,48k | N/D | 1996 |
Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer | N/D | N/D | N/D |
Mr. Peter Hong | VP, General Counsel & Secretary | N/D | N/D | N/D |
Mr. Yuh-Min Chiang Ph.D. | Senior Vice President of R&D and Product Development | N/D | N/D | N/D |
Ms. Sandra O'Donald | Senior Vice President of Business Operations | N/D | N/D | N/D |
Dr. Michael D. West Ph.D. | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. | N/D | N/D | 1953 |
Ms. Sara Riordan | Director of Medical Education | N/D | N/D | N/D |
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
L'ISS Governance QualityScore di OncoCyte Corporation al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.